<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03890822</url>
  </required_header>
  <id_info>
    <org_study_id>PROGRESSION</org_study_id>
    <nct_id>NCT03890822</nct_id>
  </id_info>
  <brief_title>Coronary Artery Disease Progression in Patients With Acute Coronary Syndromes and Diabetes Mellitus</brief_title>
  <acronym>PROGRESSION</acronym>
  <official_title>Coronary Artery Disease Progression in Patients With Acute Coronary Syndromes and Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanitas Hospital, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanitas Hospital, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 100 patients with non-ST-segment elevation acute coronary syndromes with or
      without diabetes mellitus will be included. All patients will undergo coronary angiography
      with identification of the infarct-related vessel and percutaneous revascularization with
      implantation of a stent/scaffold. After revascularization patients will undergo a combined
      positron emission tomography (PET)-coronary computed tomography (CT) protocol to quantify
      atherosclerotic burden (i.e. plaque volume) and activity (i.e. 18 fluorum-sodium-fluoride
      [18FNaF] uptake) in non-infarct related vessels, to assess calcium score (aim 1), and to
      quantify the acute results of PCI in the infarct-related vessel (aim 2). At 12-month
      follow-up, all patients will repeat longitudinal 18FNaF PET-coronary CT evaluation to
      characterize progression of atherosclerosis in the non-infarct related vessels (aim 1) and to
      quantify neointimal suppression at the site of the treated coronary segment in the
      infarct-related vessel (aim 2). Blood samples will be collected at baseline and 12 months for
      all patients.

      The aims of the study are:

        1. To evaluate coronary artery disease progression in acute coronary syndromes patients
           with and without diabetes mellitus, and to investigate the predictive value of metabolic
           profiles, patterns of circulating miRNAs and inflammatory mediators on coronary artery
           disease progression;

        2. To evaluate the progression of disease within the infarct-related vessel treated with
           the use of bioresorbable stent/bioresorbable polymer stents in diabetic and non-diabetic
           patients with acute coronary syndromes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">March 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Percentual atheroma volume</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal lumen area</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentual change in 18FNaF uptake</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minimal lumen area</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-ST-segment elevation acute coronary syndrome, with or without diabetes
        mellitus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 and &lt;80 years, evidence of non-ST-segment elevation acute coronary syndromes,
             ability to provide informed consent

        Exclusion Criteria:

          -  ST-segment elevation myocardial infarction, cardiogenic shock, suspected stent
             thrombosis, known allergy to aspirin or ticagrelor, childbearing potential, life
             expectancy &lt;1 year due to non-cardiac disease, severe chronic kidney disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giulio Stefanini, MD, PhD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Humanitas Research Hospital IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giulio Stefanini, MD, PhD, MSc</last_name>
    <phone>+390282247384</phone>
    <email>giulio.stefanini@hunimed.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gennaro Petriello, MD</last_name>
    <phone>+390282247007</phone>
    <email>gennaro.petriello@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Stefanini, MD, PhD, MSc</last_name>
    </contact>
    <contact_backup>
      <last_name>Gennaro Petriello, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 23, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Humanitas Hospital, Italy</investigator_affiliation>
    <investigator_full_name>Giulio Stefanini</investigator_full_name>
    <investigator_title>Head of Clinical Research, Cardio Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

